Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/70104
Título: Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: Results from two case-cohort studies
Autores/as: Razquin, Cristina
Ruiz-Canela, Miguel
Clish, Clary B.
Li, Jun
Toledo, Estefania
Dennis, Courtney
Liang, Liming
Salas-Huetos, Albert
Pierce, Kerry A.
Guasch-Ferré, Marta
Corella, Dolores
Ros, Emilio
Estruch, Ramon
Gómez-Gracia, Enrique
Fitó, Montse
Lapetra, Jose
Romaguera, Dora
Alonso-Gómez, Angel
Serra-Majem, Lluis 
Salas-Salvadó, Jordi
Hu, Frank B.
Martínez-González, Miguel A.
Clasificación UNESCO: 3206 Ciencias de la nutrición
320501 Cardiología
Palabras clave: Biomarkers
Cardiovascular Disease
Dietary Intervention
Metabolites
Type 2 Diabetes
Fecha de publicación: 2019
Publicación seriada: Cardiovascular Diabetology 
Resumen: Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods: Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography-tandem mass spectrometry, at baseline and after 1-year of intervention. Results: In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06-1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05-1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions: Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
URI: http://hdl.handle.net/10553/70104
ISSN: 1475-2840
DOI: 10.1186/s12933-019-0958-2
Fuente: Cardiovascular Diabetology, [ISSN 1475-2840], v. 18 (1), (Noviembre 2019)
Colección:Artículos
miniatura
Adobe PDF (911,87 kB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.